Tibolone

1. Rubin RH, Wolfson JS, Cosimi AB, et al.: Infection in the renal transplant recipient. J Med 1981, 70: 405411. Rubin RH: Infectious disease complications of renal transplantation. Kidney Int 1993, 44: 221236. Stratta R: International Congress on Immunosuppression, Orlando, FL, 1998. 4. Isada CM, Kastan BL, Goldman MD, et al.: Infectious Disease Handbook, edn. 2. Lexi Comp, Inc., 19971998. 5. Maguire GP, Wormser GP: Preventing infections in the immunocompromised: Part 2. Journal of Respiratory Diseases 1994, 15: 408. Lake KD: Management of drug interactions with cyclosporine. Pharmacotherapy 1991, 11: 110S118S. Yee GC: Pharmacokinetic interactions between cyclosporine and other drugs. Transplant Proc 1990, 22: 12031207. Drugs for tuberculosis [letter]. Med Lett Drugs Ther 1992, 24: 1012. Fishman JA: Pneumocystis carinii and parasitic infections in transplantation. Infect Dis Clin North 1995, 9: 10051044. Hadley S, Karchmer AW: Fungal infections in solid organ transplant recipients. Infect Dis Clin 1995, 19: 10451074. Harnett JD, Zeldis JB, Parfrey PS, et al.: Hepatitis B disease in dialysis and transplant patients: further epidemiologic and serologic studies. Transplantation 1987, 44: 369. Pirson Y, Alexandre GPJ, van Ypersele de Strihou C: Long-term effect of HBs antigenemia on patient survival after renal transplantation. N Engl J Med 1977, 296: 194196. Hillis WD, Hillis A, Walker WG: Hepatitis B surface antigenemia in renal transplant recipients: increased mortality risk. JAMA 1979, 242: 329. Touraine JL, Traeger J: Renal TX at the University of Lyon. Clin Transpl 1989, 5: 229238. Dhar JM, Al-Khader AA, Al-Sulaiman MH, Al-Hasani MK: The significance and implications of hepatitis B infection in renal transplant recipients. Transplant Proc 1991, 23: 1785-1786. Roy DM, Thomas PP, Dakshinamurthy KV, et al.: Long-term survival in living related donor renal allograft recipients with hepatitis B infection. Transplantation 1994, 58: 118119. Pfaff WW, Blanton JW: Hepatitis antigenemia and survival after renal transplantation. Clin Transplant 1997, 11: 476479. Fornairon S, Pol S, Legendre C, et al.: The longterm virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection. Transplantation 1996, 62: 297299. Pouteil-Noble C, Tardy JC, Chossegros P, et al.: Co-infection by hepatitis B virus and hepatitis C virus in renal transplantation: morbidity and mortality in 1098 patients. Nephrol Dial Transplant 1995, 10 suppl 6 ; : 122124. 20. Knoll GA, Tankersley MR, Lee JY, et al.: The impact of renal transplantation on survival in hepatitis Cpositive end-stage renal disease patients. J Kidney Dis 1997, 29: 608614. Thervet E, Pol S, Legendre C, et al.: Low-dose recombinant leukocyte interferon- treatment of hepatitis Cpositive end-stage renal disease patients: a pilot study. Transplantation 1994, 58: 625627. Magnone M, Holley JL, Shapiro R, et al.: Interferon induced acute renal allograft rejection. Transplantation 1995, 59: 10681070. Rostaing L, Izopet J, Baron E, et al.: Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation 1995, 59: 14261431. Rostaing L, Modesto A, Baron E, et al.: Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron 1996, 74: 512516. Yasumura T, Nakajima H, Hamashima T, et al.: Long-term outcome of recombinant INF- treatment of chronic hepatitis C in kidney transplant recipients. Transplant Proc 1997, 29: 784786. Dussol B, Charrel R, De Lamballerie X, et al.: Prevalence of hepatitis G virus infection in Kidney transplant recipients. Transplantation 1997, 64: 537539. Murthy BVR, Muerhoff AS, Desai SM, et al: Impact of pretransplantation GB virus C infection on the outcome of renal transplantation. J Soc Nephrol 1997, 8: 11641173. Fabrizi F, Lunghi G, Bacchini G, et al.: Hepatitis G virus infection in chronic dialysis patients and kidney transplant recipients. Nephrol Dial Transplant 1997, 12: 16451651 and urso. Other choices are the male-like drugs, tibolone or danazol 100 mg per day ; , progesterone injections 20 mg pill of provera daily or an injection of mpa depo-provera ; 50 mg 11once a month ; or she can take a protein extract from soybeans, a commercial preparation called bellergal ergotamine tartrate, belladonna alkaloids and phenobarbital twice a day ; or clonidine 2 mg pills twice a day.
Data collection and definitions The National Health Service Breast Screening Programme NHSBSP ; invites all women in the UK aged 5064 years for routine screening once every 3 years. From May, 1996, to March, 2001, the NHS breastscreening centres participating in the Million Women Study included the study questionnaire together with their letter of invitation for routine mammography.11 This letter is generally posted 26 weeks before the woman's screening appointment. The questionnaire is returned before women are screened and can be viewed at : millionwomenstudy . It contains questions about sociodemographic and other personal factors, including information about use of HRT and menstrual history. The study design, characteristics of the cohort, and patterns of use of HRT have been described elsewhere.1113 For a sample of the study population validation studies were done, comparing self-reported data with information in family physicians' records.14 Women were classified according to their reported use of HRT, menopausal status, and other relevant factors at recruitment--ie, at baseline. Information collected about use of HRT at baseline included: ever use; current use; age at first and last use; total duration of use; and the name of the proprietary preparation used most recently and duration of its use. The specific constituents and formulations of each proprietary preparation of HRT was obtained from the British National Formulary.15 This information was used to classify the type of preparation used as: oestrogen only; oestrogen-progestagen combination; tibolone, which contains no oestrogen or progestagen; other preparations, including progestagen only, vaginal and other local treatments, and combinations of the above types; or unknown. Users of oestrogen-only preparations were further subdivided according to the specific oestrogen constituent of the HRT equine oestrogen or oestradiol ; , its dose, and whether it was administered as an oral, transdermal, or implanted formulation. Users of combined HRT were separated into subgroups by the specific progestagen constituent medroxyprogesterone acetate, norethis419 and ursodiol.

Thus, the tibolone is left for at least 24 hours under wet conditions and valproic.

But to think that there are medical benefits from meth or coke, is just wrong. This medication works by decreasing aqueous production to lower the pressure and valacyclovir.

20 13 Shinohara Y, Ichihara J, Terada H. Remarkably enhanced expression of the type II hexokinase in rat hepatoma cell line AH130. FEBS Lett 1991; 291: 55-57 Mathupala SP, Rempel A, Pedersen PL. Glucose catabolism in cancer cells. Isolation, sequence, and activity of the promoter for type II hexokinase. J Biol Chem 1995; 270: 16918-16925 Nakashima RA, Paggi MG, Scott LJ, Pedersen PL. Purification and characterization of a bindable form of mitochondrial bound hexokinase from the highly glycolytic AS-30D rat hepatoma cell line. Cancer Res 1988; 48: 913-919 Ko YH, Pedersen PL, Geschwind JF. Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett 2001; 173: 83-91 Geschwind JF, Ko YH, Torbenson MS, Magee C, Pedersen PL. Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res 2002; 62: 39093913 Gallagher BM, Fowler JS, Gutterson NI, MacGregor RR, Wan CN, Wolf AP. Metabolic trapping as a principle of oradiopharmaceutical design: some factors resposible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. J Nucl Med 1978; 19: 1154-1161 Kapoor V, McCook BM, Torok FS. An introduction to PET-CT imaging. Radiographics 2004; 24: 523-543 Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology 2004; 231: 305-332 Ko YH, Smith BL, Wang Y, Pomper MG, Rini DA, Torbenson MS, et al. Advanced cancers: eradication in all cases using 3bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun 2004; 324: 269-275 Okada M, Kudo S, Miyazaki O, Saino T, Ekimoto H, Iguchi H, et al. Antitumoral efficacy and pharmacokinetic properties of pirarubicin upon hepatic intra-arterial injection in the rabbit V x 2 tumour model. Br J Cancer 1995; 71: 518-524 Gwak GY, Yoon JH, Kim KM, Lee HS, Chung JW, Gores GJ. Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression. J Hepatol 2005; 42: 358-364 Som P, Atkins HL, Bandoypadhyay D, Fowler JS, MacGregor RR, Matsui K, et al. A fluorinated glucose analog, 2-fluoro-2deoxy-D-glucose F-18 ; : nontoxic tracer for rapid tumor detection. J Nucl Med 1980; 21: 670-675 Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991; 32: 623-648 Oya N, Nagata Y, Ishigaki T, Abe M, Tamaki N, Magata Y, et al. Evaluation of experimental liver tumors using PET. J Nucl Med 1993; 34: 2124-2129 Messa C, Choi Y, Hoh CK, Jacobs EL, Glaspy JA, Rege S, et al. Quantification of glucose utilization in liver metastases: parametric imaging of FDG uptake with PET. J Comput Assist Tomogr 1992; 16: 684-689 Nagata Y, Yamamoto K, Hiraoka M, Abe M, Takahashi M, Akuta K, et al. Monitoring liver tumor therapy with [18F]FDG positron emission tomography. J Comput Assist Tomogr 1990; 14: 370-374 Okazumi S, Isono K, Enomoto K, Kikuchi T, Ozaki M, Yamamoto H, et al. Evaluation of liver tumors using fluorine18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. J Nucl Med 1992; 33: 333-339 Torizuka T, Tamaki N, Inokuma T, Magata Y, Yonekura Y, Tanaka A, et al. Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy. J Nucl Med 1994; 35: 1965-1969 Oya N, Nagata Y, Tamaki N, Takagi T, Murata R, Magata Y, et al. FDG-PET evaluation of therapeutic effects on VX2 liver tumor. J Nucl Med 1996; 37: 296-302 Spaepen K, Stroobants S, Dupont P, Bormans G, Balzarini J, Verhoef G, et al. [ 18 ; F]FDG PET monitoring of tumour response to chemotherapy: does [ 18 ; F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging 2003; 30: 682-688. Buy cheap tibolone Mark each box that applies 1. Family history of substance abuse Alcohol Illegal drugs Prescription drugs 2. Personal history of substance abuse Alcohol Illegal drugs Prescription drugs 3. Age mark box if 16-45 ; 4. History of preadolescent sexual abuse 5. Psychological disease Attention deficit disorder, obsessivecompulsive disorder, bipolar, schizophrenia Depression [ ] 2 Female [ ] 1 Male [ ] 3 and ativan. Binaural hearing--an ability to localize sounds and discriminate signals in noise. To achieve benefits in speech perception and sound localization, the binaural auditory system encodes two main cues: interaural time differences ITDs ; and interaural level differences ILDs ; . Although some patients are currently receiving bilateral implants, there is little known about how binaural information is encoded in neural responses when the cochlea is stimulated electrically. We established an animal model to examine the responses of binaural neurons to electrical stimulation. We placed a single channel, monopolar cochlear implant in a rabbit ear deafened with distilled water. For recording, the unanesthetized animal was stimulated via the implant ipsilaterally and via acoustic stimuli contralaterally. Leaving one ear hearing allowed us to determine neuronal responses to tones, clicks, and noise prior to electrical stimulation. Electrical stimuli consisted of single biphasic pulses and trains of pulses. Stimuli for determining binaural interactions were single pulses and clicks, and trains of pulses and clicks. Single and multiunit recordings were made from the inferior colliculus. Thresholds for the acoustic click ; stimulus tended to be low, often 0dB SPL. In contrast, the thresholds to the implant tended to be higher and less varied, corresponding to a limited dynamic range ~25dB ; . Also, the implant was able to stimulate neurons with a wide range of characteristic frequency, from 1000Hz to 20, 000Hz. This result implies that the entire cochlea was stimulated. When we varied the ILD, many neurons showed ILD tuning consistent with the good ILD sensitivity seen in bilateral implant patients. Most neurons showed little if any ITD sensitivity to the fine structure, consistent with poor ITD sensitivity in implant patients. However, we found some ITD sensitivity using trains of pulses with frequencies characteristic of envelopes e.g. 25 Hz ; . These results support suggestions that the residual ITD sensitivity seen in humans is due to envelopes.

Patient 1 * A 78-year-old woman who normally had one to two bowel motions a day presented with a 3-week history of gradual onset of more frequent and looser motions up to six times a day and occasionally at night. She had urgency and episodes of faecal incontinence. Her motions were watery. There was no improvement after she was treated with tinidazole. Her regular medications were alendronate, hydrochlorothiazide, irbesartan, raloxifene, thyroxine, temazepam, aspirin, thiamine, vitamin C, glucosamine, and evening primrose oil. She had also taken lansoprazole 30 mg capsules ; daily for 2 months to treat possible reflux. Sigmoidoscopy showed yellowish, watery stool with mucus and a few tiny scattered patches of intramucosal haemorrhage. Biopsy Figure A ; showed mild lymphocytic colitis defined by the presence of more than one lymphocyte per 20 epithelial cells ; . Lansoprazole therapy was ceased and the diarrhoea settled within 24 hours. Patient 2 * A 53-year-old woman presented to hospital with a 2-month history of diarrhoea and abdominal pain. She was admitted with suspected diverticulitis. Nine months before presentation, she had started taking lansoprazole 30 mg capsules ; daily for heartburn. She described having bowel motions seven or eight times per day, and occasionally at night. The diarrhoea had not responded to tinidazole, metronidazole or norfloxacin. Her regular medications were gemfibrozil, tibolone, indapamide and perindopril. Colonoscopy did not detect significant abnormalities. Biopsy showed mild collagenous colitis Figure B ; . Lansoprazole therapy was ceased. She was treated with loperamide, then cholestyramine and budesonide. Within 6 months, she was symptom-free without antidiarrhoeal medication. Patient 3 * A 79-year-old woman had been seen in hospital with a sudden onset of diarrhoea 5 weeks before admission, associated with 10 kg weight loss. She had taken lansoprazole 30 mg capsules ; daily for 2 weeks before the diarrhoea began. She had had up to 12 watery motions per day. The diarrhoea had not responded to norfloxacin. Her regular medications were alendronate, perindopril, potassium chloride, chlorthalidone and celecoxib. Appearance on sigmoidoscopy was normal, but biopsies Figure C ; showed mild lymphocytic colitis with occasional subepithelial collagen suggesting transition to collagenous colitis. Lansoprazole therapy was ceased, and she was treated with codeine. Her condition was much improved without antidiarrhoeal medication within a month. When reviewed 6 months later, she was having two loose motions daily, and the celecoxib 200 mg daily ; was withdrawn and bextra and tibolone. Therapy in postmenopausal women. Am. J. Obstet. Gynecol., 73, 1446 1451. Doren, M., Rubig, A., Coelingh Bennink, H.J.T. et al. 1999 ; Impact on uterine bleeding and endometrial thickness tibolone compared with continuous combined estradiol and norethisterone acetate replacement therapy. Menopause, 6, 299306. Dresner-Pollak, R., Mayer, M., Hochner-Celiniker, D. 2000 ; The decrease in serum bone-specic alkaline phosphatase predicts bone mineral density response to hormone replacement therapy in early postmenopausal women. Calcif. Tissue Int., 66, 104107. Eastell, R., Cedel, S.L., Wahner, H.W. et al. 1991 ; Classication of vertebral fractures. J. Bone Miner. Res., 6, 207215. Eiken, P., Kolthoff, N. and Nielsen, S.P. 1996 ; Effect of 10 years' hormone replacement therapy on bone mineral content in postmenopausal women. Bone, 19 Suppl. ; , S191S193. Ettinger, B. 1999 ; Personal perspective on low-dosage estrogen therapy for postmenopausal women. Menopause, 6, 273276. Ettinger, B., Black, D., Mitlak, B.H. et al. 1999 ; Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA, 282, 637645. European Consensus Development Conference on Menopause 1996 ; Human Menopause Society. Hum. Reprod., 11, 975979. Fisher, B., Costantino, J.O., Wickerham, D.L. et al. 1998 ; Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst., 90, 13711388. Gallagher, J.C. 1999 ; Moderation of the daily dose of HRT: prevention of osteoporosis. Maturitas, 33 Suppl. 1 ; , S57S63. Genant, H.K., Lucas, J., Weiss, St. et al. 1997 ; Low-dose esteried estrogen therapy. Effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Arch. Intern. Med., 157, 26092615. Gorai, I., Chaki, O., Taguchi, Y. et al. 1999 ; Early postmenopausal bone loss is prevented by estrogen and partially by 1a-OH.vitamin D3: therapeutic effects of estrogen and or 1a-OH-vitamin D3. Calcif. Tissue Int., 65, 16 22. Grady, D., Rubin, S.M., Petitti, D.B. et al. 1992 ; Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann. Intern. Med., 117, 10161037. Grady, D., Gebretsadik, T., Kerlikowke, K. et al. 1995 ; Hormone replacement therapy and endometrial cancer: a meta-analysis. Obstet. Gynecol., 85, 304313. Hammar, M., Christau, S., Nathorst-Boos, J. et al. 1998 ; A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br. J. Obstet. Gynaecol., 105, 904911. Harris, S.T., Watts, N.B., Genant, H.K. et al. 1999 ; Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA, 282, 13441352. Hart, D.M., Abdalla, H., Clarke, D. and Lindsay, R. 1984 ; Preservation of bone mass in postmenopausal women during therapy with estrogen and progestogens. In Christiansen, C., Arnaud, C.D., Nordin, B.E.C. et al. Eds Osteoporosis. Proceedings of the International Symposium on Osteoporosis, Copenhagen, June3-8, Aarlborg Stiftsbogtrykkeri, pp697699 Henry, D., Robertson, J., O'Connell, D. et al. 1998 ; A systematic review of the skeletal effects of estrogen therapy in postmenopausal women. I. An assessment of the quality of randomized trials published between 1977 and 1995. Climacteric, 1, 92111. Hirvonen, E., Caccatiore, B., Wahlstrom, T. et al. 1997 ; Effects of transdermal oestrogen therapy in postmenopausal women: a comparative study of an oestradiol gel and an oestradiol delivering patch. Br. J. Obstet. Gynaecol., 104 Suppl. 16 ; , 2631. Hosking, D., Chilvers, C.E.D., Christiansen, C. et al. 1998 ; Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N. Engl. J. Med., 338, 485492. Hulley, S., Grady, D., Bush, T. et al for the Heart and Estrogen Progestin Replacement Study HERS ; Research Group 1998 ; Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA, 280, 605613. Itoi, H., Minakami, H. and Sato, I. 1997 ; Comparison of the long-term effects of oral estriol with the effects of conjugated estrogen, 1a-hydroxyvitamin D3 and calcium lactate on vertebral bone loss in early menopausal women. Maturitas, 28, 1117. Klehr-Bathmann, I. and Kuhl, H. 1995 ; Formation of ethinylestradiol in postmenopausal women during continuous treatment with a combination of estradiol, estriol and norethisterone acetate. Maturitas, 21, 245250. Allergies anti-depressants anti-infectives anti-psychotics anti-smoking antibiotics asthma cancer cardio & blood cholesterol diabetes epilepsy gastrointestinal hair loss herpes hiv hormonal men's health muscle relaxers other pain relief parkinson's rheumatic skin care weight loss women's health allegra atarax benadryl clarinex claritin clemastine periactin phenergan pheniramine zyrtec anafranil celexa cymbalta desyrel effexor elavil, endep luvox moclobemide pamelor paxil prozac reboxetine remeron sinequan tofranil wellbutrin zoloft albenza amantadine aralen flagyl grisactin isoniazid myambutol pyrazinamide sporanox tinidazole vermox abilify clozaril compazine flupenthixol geodon haldol lamictal lithobid loxitane mellaril risperdal seroquel nicotine zyban achromycin augmentin bactrim biaxin ceclor cefepime ceftin chloromycetin cipro, ciloxan cleocin duricef floxin, ocuflox gatifloxacin ilosone keftab levaquin minomycin noroxin omnicef omnipen-n oxytetracycline rifater rulide suprax tegopen trimox vantin vibramycin zithromax advair aerolate, theo-24 brethine, bricanyl ketotifen metaproterenol proventil, ventolin serevent singulair arimidex casodex decadron eulexin femara levothroid, synthroid nolvadex provera, cycrin ultram vepesid zofran acenocoumarol aceon adalat, procardia altace atenolol amlodipine avapro caduet calan, isoptin capoten captopril hctz cardizem cardura catapres cilexetil, atacand clonidine, hctz combipres cordarone coreg coumadin cozaar dibenzyline diovan fosinopril hydrochlorothiazide hytrin hyzaar inderal ismo, imdur isordil, sorbitrate lanoxin lasix lercanidipine lopressor lotensin lozol micardis minipress moduretic normadate norpace norvasc plavix plendil prinivil, zestril prinzide rythmol tenoretic tenormin trental valsartan hctz vaseretic vasodilan vasotec zebeta crestor lipitor lopid mevacor pravachol tricor zocor accupril actos alpha-lipoic acid amaryl avandia diamicron mr gliclazide metformin glucophage glucotrol glucotrol xl glucovance lyrica micronase orinase prandin precose starlix depakote dilantin lamictal neurontin sodium valproate tegretol topamax trileptal valparin aciphex asacol bentyl cinnarizine colospa compazine cromolyn sodium cytotec imodium motilium nexium nexium fast pepcid ac pepcid complete prevacid prilosec propulsid protonix reglan stugil zantac zelnorm zofran propecia, proscar famvir rebetol valtrex zovirax combivir duovir-n epivir pyrazinamide retrovir sustiva videx viramune zerit ziagen aldactone calciferol danocrine decadron prednisone provera, cycrin synthroid avodart flomax hytrin levitra propecia, proscar viagra lioresal soma tizanidine ibuprofen zanaflex accupril alpha-lipoic acid amantadine aralen arcalion aricept ascorbic acid benadryl bentyl betahistine calciferol carbimazole compazine cyklokapron ddavp, stimate detrol dihydroergotoxine ditropan dramamine exelon florinef imitrex imuran isoniazid lasix melatonin myambutol nimotop orap persantine piracetam pletal quinine rifampin rifater rocaltrol strattera ticlid tiotropium urecholine urispas urso vermox zyloprim acetylsalicylic acid advil, medipren celebrex flunarizine imitrex ketorolac maxalt ponstel tylenol ultram benadryl ditropan eldepryl requip sinemet trivastal advil, medipren arava colchicine decadron feldene indocin sr mobic naprelan naprosyn zyloprim betamethasone differin nizoral oxsoralen prograf retin-a xenical advil, medipren allyloestrenol clomid, serophene diflucan evista folic acid fosamax isoflavone nexium parlodel ponstel prevacid prilosec progesterone provera, cycrin rocaltrol tibolone generic norpace generic name: disopyramide ; qty and cialis.

Exist for Taiwan to participate in the global R & D and to establish sound IND consultation process. These efforts will ultimately benefit the health of Taiwan populations. References 1. International Conference on Harmonisation of ICH ; ifpma ich1 . 1997. Guideline for ethnic factors in the acceptability of foreign clinical data 2. Lin M, Chu CC, Chang SL, et al. 2001. The origin of Minnan and Hakka, the so-called "Taiwanese", inferred by HLA study. Tissue Antigen 57: 192-9 3. Yang TS, Tsan SH, Chen CR, et al. 1999. Evaluation of conjugated estrogen plis medroxyprogesterone acetate versus tibolone in early postmenopausal Chinese women. 4. Shih WJ. 2001. Clinical trials for drug registrations in Asian-Pacific countries: Proposal for a new paradigm from a statistical perspective. Controllled Clinical Trials 22: 357366 5. Wang M and Kung MF. 2001. Statistics in bridging study: sample size reduction and similarity in effect size. Symposium on Statistical Methodology for Evaluation of Bridging Evidence: 1-14. HORMONE REPLACEMENT THERAPY HRT ; AND BREAST CANCER IMPORTANT NEW INFORMATION You may have seen in the news that a large study in the UK, the Million Women Study, has just published its results on the risk of breast cancer with various types of HRT. This study shows that the level of risk associated with use of combined oestrogen plus progestogen ; HRT products is substantially higher than previously thought. If, after reading the information below, you are concerned, make a routine appointment to see your doctor. Use of HRT In the UK, HRT products are licensed for helping relieve the unpleasant symptoms of the menopause, including hot flushes, vaginal dryness and night sweats. Some HRT products are also licensed for the longer-term prevention of osteoporosis, which can cause bone fractures. Million Women Study findings This study looked at the effect of different types of HRT on the risk of breast cancer in nearly a million postmenopausal women in the UK. The results confirm that oestrogen-only HRT causes a small increase in the risk of breast cancer. Combined oestrogen plus progestogen ; HRT products were shown to increase the risk of breast cancer more than oestrogen-only therapy. For oestrogen-only products, an extra 1-2 cases of breast cancer are expected to be diagnosed per 1000 women after 5 years of use and an extra 5 cases per 1000 women after 10 years of use, compared to women not using HRT. For combined HRT an extra 6 cases of breast cancer are expected to be diagnosed per 1000 women after 5 years of using combined HRT and an extra 19 cases per 1000 women after 10 years, compared to women not using HRT. This study also shows that the use of tibolone Livial - a different type of HRT product ; increases the risk of breast cancer compared to not using HRT. However, the risk is not as high as with combined HRT. The longer HRT is used, the higher the risk of breast cancer. In all cases, the risk of breast cancer begins to decline when HRT is stopped and by 5 years reaches the same level as in women who have never taken HRT. Take home message This new study confirms what we already knew about the risk of breast cancer with oestrogen-only preparations and provides important new information about the risk with combined HRT and tibolone. If you are concerned about this information, make a routine appointment to see your doctor. These new results may present you and your doctor with a dilemma about your HRT treatment. It is important that you note any changes with your breasts and, if you are 50 or over, attend for breast screening for further information see cancerscreening.nhs breastscreen breastawareness. html ; . Further information Further information and advice may be found on the Medicines and Healthcare products Regulatory Agency's website mhra.gov ; . Here you can find more details about the other risks and benefits of HRT treatment, which may help to answer some of the questions you may have about these new findings. NHS Direct may also be able to answer your questions Tel 0845 4647. And kevin i took a responce you gave me onetime about the folliculitis with some drugs you mentioned. Table 2: Residual protein concentration. The protein concentration of the cleared plasma samples was tested to ensure sufficient protein was removed from the plasma. 99.4% total protein was removed from the samples.